MedTrace Logo

Effect of Camel Milk With Probiotic on Type 2 Diabetes Mellitus

NCT04296825 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2020-03-05

No results posted yet for this study

Summary

The purpose of this study is to investigate the effects of dietary supplement with Camel Milk containing Bifidobacterium animalis A6 on the plasma glucose and other related cytokines in patients with type 2 diabetes mellitus. 45 patients with type 2 diabetes mellitus were recruited, and a Double Blind Randomized Parallel Controlled Trial was performed. The fasting glycaemia, 2 hour postprandial glycaemia, insulin, uric acid and serum lipid (total cholesterol, total triglyceride, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol ) were measured as Primary Outcome. The Fecal microbiome, fecal metabolites, gut hormones (amylin, ghrelin, glucagon-like peptide 1, pancreatic polypeptide), inflammation cytokines (TNF-α, IL-6, MCP-1), myokines (FGF-21, irisin, osteocrin/musclin, osteonectin) and adipokines (adiponectin, resistin, lipocalin-2, adipsin) and body composition analysis were also assessed.

Conditions

Interventions

DIETARY_SUPPLEMENT

Camel milk containing Bifidobacterium animalis A6

Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.

DIETARY_SUPPLEMENT

Camel milk

Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.

DIETARY_SUPPLEMENT

Bifidobacterium animalis A6

Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.

DIETARY_SUPPLEMENT

Cow milk

Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.

Sponsors & Collaborators

  • Beijing Chinese Medicine Hospital-Pinggu Hospital

    collaborator UNKNOWN

  • China Agricultural University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
68 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2018-06-09
Completion
2018-07-09

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04296825 on ClinicalTrials.gov